Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.
Los Angeles Times (LT) - WEDNESDAY January 29, 1997 Edition: Home Edition Section: Business Page: 2 Pt. D Word Count: 597
Chris Kraul; Times Staff Writer
This time around, the company is Agouron Pharmaceuticals. Its Viracept is one of a new class of HIV drugs called protease inhibitors that have achieved encouraging results in the battle against the virus that causes AIDS. If approved, Wall Street is predicting a $600-million annual market for Viracept.
Last week, Agouron presented data from its final phase of clinical trials at a medical conference in Washington, and the results caused a flurry of optimism in the medical community, not to mention renewed interest on Wall Street.
Big bucks are riding on Agouron: The company has raised close to $500 million from investors, even though it has yet to generate any drug revenue.
Although down from last week's peak, Agouron's Tuesday stock close of $79.625 in over-the-counter trading is more than double its price a year ago and up from a low of $15 a share three years ago.
The optimism is founded not just on the positive clinical results, but also because the FDA is now processing--and in some cases approving--clinical drugs with newfound dispatch, especially those that purport to treat AIDS and cancer, said PaineWebber biotechnology analyst Douglas Lind.
If it receives FDA approval, Agouron's Viracept would be the fourth protease inhibitor to get the agency's green flag in the last 14 months--which for the FDA equates to a veritable flurry of approvals.
Agouron, founded in 1984 by Chief Executive Peter Johnson and other UC San Diego scientists, has a stock market value of more than $1 billion. Employees total 540, more than any other San Diego biotechnology company, and double its work force from a year ago.
But the community could be forgiven a little skepticism. Observers of this city's biotechnology industry remember how another local company's high hopes were dashed when FDA approval, thought to be all but a formality, didn't come through as planned.
The company was Gensia Pharmaceuticals, founded by alumni of San Diego-based Hybritech, which was sold to Eli Lilly in 1985 for $485 million, then San Diego's biggest biotechnology success. By the early 1990s, Gensia seemed on track to receive FDA approval for Protara, a drug to limit heart tissue damage in bypass surgery patients.
Partly because of its pedigree, Gensia was also able to raise hundreds of millions of dollars and saw its stock price rise as high as $42 in 1992, as it passed through clinical trials with flying colors.
But in October 1994 came the crushing news: The FDA ruled that Protara provided no more meaningful advantages to surgical patients than a placebo. Gensia stock now trades in the $4 range.
Housing's Back
San Diego County's new housing market picked up in 1996, posting the highest number of units sold since 1990, said Russ Valone, president of Market Profiles, a San Diego-based real estate market research firm. Developers sold 4,708 new detached single-family houses, an 19% gain over last year's 3,970 units.
Perhaps most indicative of a recovery, Valone said the county saw sales of 900 "luxury" units, those priced at more than $300,000.
That's up 50% from 1995 and a good sign of "reinforced consumer confidence in the housing market."
The average price of new detached units sold in 1996 in the county was $242,700, up 4.3% from the previous year's $233,300.
CAPTION: Photo: Peter Johnson, president and CEO of Agouron, awaits FDA approval of the company's AIDS drug. MICHAEL POCHE / For The Times
970129
LT970113
Copyright © 1997 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .